Published in Genome Biol on November 25, 2014
The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev (2016) 0.99
Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7. Proc Natl Acad Sci U S A (2016) 0.96
Interrogating the Plasmodium Sporozoite Surface: Identification of Surface-Exposed Proteins and Demonstration of Glycosylation on CSP and TRAP by Mass Spectrometry-Based Proteomics. PLoS Pathog (2016) 0.91
A broad analysis of resistance development in the malaria parasite. Nat Commun (2016) 0.84
Next-Generation Sequencing of Plasmodium vivax Patient Samples Shows Evidence of Direct Evolution in Drug-Resistance Genes. ACS Infect Dis (2015) 0.80
From within host dynamics to the epidemiology of infectious disease: Scientific overview and challenges. Math Biosci (2015) 0.78
Plasmodium falciparum: multifaceted resistance to artemisinins. Malar J (2016) 0.78
The Stapled AKAP Disruptor Peptide STAD-2 Displays Antimalarial Activity through a PKA-Independent Mechanism. PLoS One (2015) 0.77
Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria. Antimicrob Agents Chemother (2016) 0.76
Human infectious diseases in the genomics era: where do we go from here? Genome Biol (2014) 0.75
Prevalence of K13-propeller gene polymorphisms among Plasmodium falciparum parasites isolated from adult symptomatic patients in northern Uganda. BMC Infect Dis (2016) 0.75
Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol (2016) 0.75
Monitoring artemisinin resistance in Plasmodium falciparum: comparison of parasite clearance time by microscopy and real-time PCR and evaluation of mutations in Pfatpase6 gene in Odisha state of India. Parasitol Res (2015) 0.75
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (2012) 48.17
Genome sequence of the human malaria parasite Plasmodium falciparum. Nature (2002) 37.89
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med (2008) 17.65
Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature (2002) 12.09
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet (2012) 11.82
A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature (2013) 11.03
Intercontinental spread of pyrimethamine-resistant malaria. Science (2004) 8.73
Artemisinins target the SERCA of Plasmodium falciparum. Nature (2003) 7.72
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis (2012) 6.94
Genetic analysis of the human malaria parasite Plasmodium falciparum. Science (1987) 6.48
A major genome region underlying artemisinin resistance in malaria. Science (2012) 6.25
Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science (2002) 6.19
Evolutionary and historical aspects of the burden of malaria. Clin Microbiol Rev (2002) 6.07
Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis (2013) 6.06
Spiroindolones, a potent compound class for the treatment of malaria. Science (2010) 5.94
Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J (2011) 5.65
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol (2005) 4.92
Identification of an antimalarial synthetic trioxolane drug development candidate. Nature (2004) 4.57
Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis (2006) 4.21
Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A (2012) 4.10
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol (2009) 3.84
High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J Infect Dis (2010) 3.81
Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol (2013) 3.73
Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell (1989) 3.71
Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One (2013) 3.66
Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg (1996) 3.36
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. Science (2011) 3.30
Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. Science (1989) 3.25
Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis (2014) 3.21
Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother (2012) 3.12
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science (2011) 3.07
Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob Agents Chemother (2010) 3.04
Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A (2011) 2.94
In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis (2009) 2.80
Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. Trends Parasitol (2013) 2.76
Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother (2010) 2.68
Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system. Nat Biotechnol (2014) 2.65
Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics (2011) 2.53
Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7. Proc Natl Acad Sci U S A (1991) 2.49
Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat Genet (2010) 2.48
Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis (2013) 2.47
The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med (2012) 2.42
Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol (2009) 2.23
Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol Microbiol (2007) 2.18
Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob Agents Chemother (2006) 2.16
Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med (2014) 2.07
Spiroindolone KAE609 for falciparum and vivax malaria. N Engl J Med (2014) 1.99
Artemisinin: discovery from the Chinese herbal garden. Cell (2011) 1.99
Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS One (2014) 1.96
Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proc Natl Acad Sci U S A (2013) 1.83
PfCRT and its role in antimalarial drug resistance. Trends Parasitol (2012) 1.63
Artemisinin resistance is a clear and present danger. Trends Parasitol (2013) 1.62
Sequence-based association and selection scans identify drug resistance loci in the Plasmodium falciparum malaria parasite. Proc Natl Acad Sci U S A (2012) 1.58
Phenotypic and genotypic analysis of in vitro-selected artemisinin-resistant progeny of Plasmodium falciparum. Antimicrob Agents Chemother (2011) 1.57
Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families. PLoS Genet (2013) 1.54
A genetic approach to the de novo identification of targets of strain-specific immunity in malaria parasites. Proc Natl Acad Sci U S A (2005) 1.45
Mechanisms of in vitro resistance to dihydroartemisinin in Plasmodium falciparum. Mol Microbiol (2012) 1.42
The genetics of the dorsal-Bicaudal-D region of Drosophila melanogaster. Genetics (1986) 1.41
Efficient CRISPR-Cas9-mediated genome editing in Plasmodium falciparum. Nat Methods (2014) 1.31
Directional selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu loci of Plasmodium falciparum in Kenyan children treated with ACT. J Infect Dis (2014) 1.29
Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa. J Infect Dis (2009) 1.26
Asexual populations of the human malaria parasite, Plasmodium falciparum, use a two-step genomic strategy to acquire accurate, beneficial DNA amplifications. PLoS Pathog (2013) 1.25
First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol (2013) 1.15
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance. Antimicrob Agents Chemother (2010) 1.14
Iron and heme metabolism in Plasmodium falciparum and the mechanism of action of artemisinins. Curr Opin Microbiol (2013) 1.12
Molecular and chemical regulation of the Keap1-Nrf2 signaling pathway. Molecules (2014) 1.08
The challenge of artemisinin resistance can only be met by eliminating Plasmodium falciparum malaria across the Greater Mekong subregion. Malar J (2014) 1.06
Purified E255L mutant SERCA1a and purified PfATP6 are sensitive to SERCA-type inhibitors but insensitive to artemisinins. J Biol Chem (2010) 1.02
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother (2014) 1.01
Plasmodium falciparum clearance is rapid and pitting independent in immune Malian children treated with artesunate for malaria. J Infect Dis (2014) 1.01
The Plasmodium falciparum Ca(2+)-ATPase PfATP6: insensitive to artemisinin, but a potential drug target. Biochem Soc Trans (2011) 0.97
Artemisinin resistance in Plasmodium falciparum: what is it really? Trends Parasitol (2013) 0.91
A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother (2014) 0.90
Keap1 modulates the redox cycle and hepatocyte cell cycle in regenerating liver. Cell Cycle (2014) 0.82
Functional profiling of the Saccharomyces cerevisiae genome. Nature (2002) 36.10
Discovery of gene function by expression profiling of the malaria parasite life cycle. Science (2003) 10.57
Spiroindolones, a potent compound class for the treatment of malaria. Science (2010) 5.94
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci U S A (2008) 4.80
Global analysis of transcript and protein levels across the Plasmodium falciparum life cycle. Genome Res (2004) 3.63
Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility. Nat Chem Biol (2008) 3.23
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science (2011) 3.07
The Plasmodium falciparum sexual development transcriptome: a microarray analysis using ontology-based pattern identification. Mol Biochem Parasitol (2005) 3.02
A systematic map of genetic variation in Plasmodium falciparum. PLoS Pathog (2006) 2.92
Molecular mechanism for switching of P. falciparum invasion pathways into human erythrocytes. Science (2005) 2.81
The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med (2012) 2.42
Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol (2009) 2.23
The Plasmodium eukaryotic initiation factor-2alpha kinase IK2 controls the latency of sporozoites in the mosquito salivary glands. J Exp Med (2010) 2.08
Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe (2012) 2.05
Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell (2007) 1.90
Parallel identification of new genes in Saccharomyces cerevisiae. Genome Res (2002) 1.89
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem (2010) 1.84
The Ume6 regulon coordinates metabolic and meiotic gene expression in yeast. Proc Natl Acad Sci U S A (2002) 1.74
Whole-genome sequencing and microarray analysis of ex vivo Plasmodium vivax reveal selective pressure on putative drug resistance genes. Proc Natl Acad Sci U S A (2010) 1.74
Piperaquine resistance is associated with a copy number variation on chromosome 5 in drug-pressured Plasmodium falciparum parasites. Antimicrob Agents Chemother (2011) 1.67
Evidence-based annotation of the malaria parasite's genome using comparative expression profiling. PLoS One (2008) 1.61
Previously uncharacterized genes in the UV- and MMS-induced DNA damage response in yeast. Proc Natl Acad Sci U S A (2002) 1.61
Antimalarial drug discovery - approaches and progress towards new medicines. Nat Rev Microbiol (2013) 1.60
Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe (2013) 1.58
Treasures and traps in genome-wide data sets: case examples from yeast. Nat Rev Genet (2002) 1.57
Mitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen families. PLoS Genet (2013) 1.54
Excess polymorphisms in genes for membrane proteins in Plasmodium falciparum. Science (2002) 1.52
A Plasmodium gene family encoding Maurer's cleft membrane proteins: structural properties and expression profiling. Genome Res (2004) 1.49
A large-scale operational study of home-based therapy with ready-to-use therapeutic food in childhood malnutrition in Malawi. Matern Child Nutr (2007) 1.48
In silico discovery of transcription regulatory elements in Plasmodium falciparum. BMC Genomics (2008) 1.48
In vivo transcriptome of Plasmodium falciparum reveals overexpression of transcripts that encode surface proteins. J Infect Dis (2005) 1.46
Validation of isoleucine utilization targets in Plasmodium falciparum. Proc Natl Acad Sci U S A (2011) 1.46
In silico gene function prediction using ontology-based pattern identification. Bioinformatics (2004) 1.44
A systems-based analysis of Plasmodium vivax lifecycle transcription from human to mosquito. PLoS Negl Trop Dis (2010) 1.31
A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor. ACS Chem Biol (2011) 1.31
A systematic approach to understand the mechanism of action of the bisthiazolium compound T4 on the human malaria parasite, Plasmodium falciparum. BMC Genomics (2008) 1.27
Genome scanning of Amazonian Plasmodium falciparum shows subtelomeric instability and clindamycin-resistant parasites. Genome Res (2010) 1.27
Monitoring the chromosome 2 intraerythrocytic transcriptome of Plasmodium falciparum using oligonucleotide arrays. Am J Trop Med Hyg (2002) 1.26
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents. J Med Chem (2012) 1.22
Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J Infect Dis (2013) 1.15
The paradoxical population genetics of Plasmodium falciparum. Trends Parasitol (2002) 1.14
Abnormal gut integrity is associated with reduced linear growth in rural Malawian children. J Pediatr Gastroenterol Nutr (2012) 1.10
Infection of laboratory-colonized Anopheles darlingi mosquitoes by Plasmodium vivax. Am J Trop Med Hyg (2014) 1.10
Large-scale annotation of small-molecule libraries using public databases. J Chem Inf Model (2007) 1.08
Using genetic methods to define the targets of compounds with antimalarial activity. J Med Chem (2013) 1.06
KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. Antimicrob Agents Chemother (2013) 1.03
Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials. ACS Chem Biol (2014) 1.03
Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design. Proc Natl Acad Sci U S A (2012) 1.02
Target identification and validation of novel antimalarials. Future Microbiol (2011) 1.00
Direct transfer of whole genomes from bacteria to yeast. Nat Methods (2013) 0.99
Identification of pathogen genomic variants through an integrated pipeline. BMC Bioinformatics (2014) 0.97
Elucidating genetic diversity with oligonucleotide arrays. Chromosome Res (2005) 0.97
Whole genome sequencing analysis of Plasmodium vivax using whole genome capture. BMC Genomics (2012) 0.96
Large-scale mutagenesis and functional genomics in yeast. Funct Integr Genomics (2002) 0.94
In vivo transcriptional profiling of Plasmodium falciparum. Malar J (2004) 0.94
Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites. Vaccine (2011) 0.92
Coordinated functions of WSS1, PSY2 and TOF1 in the DNA damage response. Nucleic Acids Res (2004) 0.91
Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria. Emerg Infect Dis (2013) 0.90
Nuclear repositioning precedes promoter accessibility and is linked to the switching frequency of a Plasmodium falciparum invasion gene. Cell Host Microbe (2012) 0.89
Genomics, systems biology and drug development for infectious diseases. Mol Biosyst (2007) 0.88
A key role for lipoic acid synthesis during Plasmodium liver stage development. Cell Microbiol (2013) 0.87
Genome wide analysis of inbred mouse lines identifies a locus containing Ppar-gamma as contributing to enhanced malaria survival. PLoS One (2010) 0.84
Perspectives: The missing pieces. Nature (2012) 0.84
Using expression information to discover new drug and vaccine targets in the malaria parasite Plasmodium falciparum. Pharmacogenomics (2005) 0.82
Genomics and systems biology in malaria drug discovery. Curr Opin Investig Drugs (2010) 0.81
Detection of bacterial spores with lanthanide-macrocycle binary complexes. J Am Chem Soc (2009) 0.80
Next-Generation Sequencing of Plasmodium vivax Patient Samples Shows Evidence of Direct Evolution in Drug-Resistance Genes. ACS Infect Dis (2015) 0.80
Epidemiology: resistance mapping in malaria. Nature (2013) 0.79
Identification of the Plasmodium berghei resistance locus 9 linked to survival on chromosome 9. Malar J (2013) 0.78
Noncoding RNA, antigenic variation, and the virulence genes of Plasmodium falciparum. BMC Biol (2011) 0.78
Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature (2016) 0.77
Using the genome to dissect the molecular basis of drug resistance. Future Microbiol (2006) 0.76
Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle. J Med Chem (2016) 0.75
Antimalarial drug discovery - approaches and progress towards new medicines. Nat Rev Microbiol (2017) 0.75